Zacks Investment Research·1d ago
APi (APG) is an Incredible Growth Stock: 3 Reasons WhyAPi (APG) is well positioned to outperform the market, as it exhibits above-average growth in financials.
APi Group's revenue grew 22.5% year over year to roughly $2.6B in 2026Q3, but its gross margin has held in a narrow 28% to 31% band and operating margin of 7.9% trails higher-margin peers, suggesting growth is largely acquisition-led rather than driven by structural profitability gains.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue expanded to roughly $2.6B with a 22.5% year-over-year increase, yet a 7.9% operating margin and 4.5% net margin suggest limited operating leverage relative to growth.
APi Group's Safety Services segment offers high-margin recurring revenue, contributing to stable financial performance and long-term growth potential.
The company's disciplined acquisition strategy, including the recent purchase of Onyx-Fire Protection Services, enhances its market position and revenue growth.
APi Group's inspection-led business model drives recurring revenue streams, providing predictability and scalability in its operations.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $0.50+6.3% vs $0.47 | $2.6B+6.4% vs $2.4B |
Q3 2026 Jul 30, 2026 | $0.44+1.3% vs $0.43 | $2.3B+2.2% vs $2.2B |
Q2 2026 Apr 30, 2026 | $0.32+5.1% vs $0.30 | $2.0B+3.1% vs $1.9B |
Q1 2026 Feb 25, 2026 | $0.44+6.5% vs $0.41 | $2.1B+1.2% vs $2.1B |
APi (APG) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The consensus price target hints at a 36.6% upside potential for APi (APG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that multiple clinical and preclinical studies have been selected at the 68th American Society of Hematology (ASH) Annual Meeting, involving four of the Company's proprietary innovative drug candidates, namely olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China, lisaftoclax (APG-2575), a potentially best-in-class Bcl-2 inhibitor approved in China, APG-5918, a PRC2/EED inhibitor, and APG-3288, a BTK protein degrader. These new data presentations highlight the Company's global innovation capabilities in hematologic malignancies. Notably, APG-5918 was selected for an oral presentation upon the first disclosure of its clinical data.
Does APi (APG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Benchmark APG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for APi Group Corporation (APG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.87 | $17.71B | 48.11 | 12.72% | 4.12% | 10.56% | — | |
| $262.91 | $4.09B | 21.39 | 8.79% | 4.48% | 26.32% | — | |
| $540.90 | $81.17B | 48.78 | 19.76% | 4.54% | 17.58% | 0.07% | |
| $174.10 | $13.76B | 28.18 | 16.22% | 2.85% | 13.54% | — | |
| $66.22 | $1B | 16.22 | 20.46% | 8.19% | 18.99% | — | |
| $9.33 | $2.12B | 72.78 | 7.86% | 1.44% | 3.63% | — |
APi Group Corporation (APG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
APi Group Corporation (APG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
Jul 2, 2026·SEC
Get notified when APG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APi Group Corporation (APG) stock FAQ — growth, dividends, profitability & financials explained
APi Group Corporation (APG) reported $8.91B in revenue over the trailing twelve months. Revenue was $7.91B in fiscal year 2025. That is 160% more than the $3.05B of fiscal year 2017.
APi Group Corporation (APG) grew revenue by 16.4% over the trailing twelve months, compared with the twelve months before.
Yes. APi Group Corporation (APG) earned $367.0M in net income over the trailing twelve months (a 4.1% net margin).
APi Group Corporation (APG) had a return on equity (ROE) of 10.6% over the trailing twelve months. That is in line with the market's typical 10-15%.
APi Group Corporation (APG) generated $673.0M in free cash flow over the trailing twelve months.
